Cure My Disease

Don't miss your cure!

 Log in / Sign up

New generic combo pill for high blood pressure put to the test

NCT ID NCT07584304

Not yet recruiting Knowledge-focused Sponsor: Yuhan Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will check if a new generic drug called YHP2508C works the same as the reference drug YHR2603 in 44 healthy adults. Participants will take a single dose of each drug under fasting conditions, and researchers will measure drug levels in the blood. The goal is to see if the generic version is bioequivalent, meaning it delivers the same amount of active ingredients into the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
YHP2508C (a combination of amlodipine, telmisartan, and chlorthalidone)
What this could lead to
If successful, this could show that the test drug is a safe and effective generic alternative to the reference drug, potentially offering a lower-cost treatment option for high blood pressure.
What could go wrong
This is an early-phase bioequivalence study in healthy volunteers, not patients. It only measures how the drug is absorbed and processed, not whether it works for the intended condition. Results may not predict real-world effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SUBJECTS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.